Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Ultragenyx Pharmaceutical Inc.

Get SEC filing alerts via email and in your feed for Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultrarare genetic diseases. Its portfolio includes approved biologics and gene therapies targeting conditions like XLH, MPS VII, and HoFH. The company emphasizes efficient drug development, strategic licensing, and global commercialization to address high unmet medical needs in niche markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Ultragenyx Pharmaceutical Inc.

1
1
Ultragenyx Pharmaceutical Inc. Ultragenyx Reports $136 Million Revenue in Q1 2026, Faces Decline in Crysvita Sales

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Ultragenyx Pharmaceutical Inc. Ultragenyx Reports $673 Million Revenue for Fiscal Year 2025, Initiates Workforce Reduction

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Ultragenyx Pharmaceutical Inc. Ultragenyx Reports $159.9 Million Revenue in Q3 2025, Despite $180.4 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Ultragenyx Pharmaceutical Inc. Ultragenyx Reports $166.5 Million Revenue in Q2 2025, Despite $115 Million Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Ultragenyx Pharmaceutical Inc. Ultragenyx Reports $139.3 Million Revenue in Q1 2025, Driven by 46% Increase in Product Sales

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Reports $560.2M Revenue and $569.2M Net Loss for 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Reports 42% Revenue Growth, Narrowed Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments